Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06924021 · ClinicalTrials.gov registry record
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
A clinical trial of Age-related Macular Degeneration, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 14
- Study locations
NCT06924021: Recruiting study of Age-related Macular Degeneration, sponsored by University of Wisconsin, Madison.
NCT06924021 is a study of Age-related Macular Degeneration that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 1,000 participants, below the 1,494-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (33% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06924021, a study of Age-related Macular Degeneration, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 14
- Study locations
Study Summary
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Primary Outcome
A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by classifying AMD status. The goal is to have: * 20% participants with no AMD * 30% participants with Early AMD * 30% participants with Intermediate AMD * 10% participants with Geographic Atrophy (GA) * 10% participants with Neovascular age-related macular dege
Conditions Studied
Interventions
- OTHER Retinal Imaging
Study Locations (14)
Other
- Charles Research Center - Buenos Aires
- Adelaide Eye and Retina Centre - Adelaide
- Centre Hospialier Intercommunal de Paradis (Centre Monticelli Paradis) - Marseille
- University of Bonn - Department of Ophthalmology - Bonn
- Aga Khan University - Karachi
Texas
- Retina Foundation of the Southwest - Dallas
- Valley Retina Institute - McAllen
- Retina Consultants of Texas (Houston) - The Woodlands
Tamil Nadu
- Sankara Nethralaya, Medical Research Foundation - Chennai
- Aravind Eye Hospital - Chennai
North Dakota
- Bergstrom Eye Research LLC - Fargo
Pennsylvania
- Erie Retina Research - Erie
Utah
- University of Utah - John A. Moran Eye Center - Salt Lake City
Wisconsin
- University Station Eye Care Clinic - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2026-11 |
What NCT06924021 shows while recruiting
NCT06924021 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,494-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Retinal Imaging is the first listed.
NCT06924021 lists 14 locations in 7 states (Other, Texas, Tamil Nadu).
Frequently Asked Questions
What is clinical trial NCT06924021 about?
NCT06924021 is a clinical study titled "Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)". 1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial I...
What is the current status of trial NCT06924021?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-05-12. Estimated completion is 2026-11.
What conditions does trial NCT06924021 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT06924021?
The interventions under investigation include: Retinal Imaging (OTHER).
Who is sponsoring clinical trial NCT06924021?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06924021 being conducted?
This trial has 14 study locations across North Dakota, Pennsylvania, Texas, Utah, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06924021's enrollment target sits among peer trials
1,000 5th of 74 higher than 70 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI